|
GRLF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.53029999999865E-05 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.93819999999967E-05 |
| Normal-vs-Stage2 |
5.660000E-01 |
| Normal-vs-Stage3 |
2.15719999999697E-05 |
| Normal-vs-Stage4 |
2.25350000004898E-06 |
| Stage1-vs-Stage2 |
2.076500E-03 |
| Stage1-vs-Stage3 |
4.211200E-01 |
| Stage1-vs-Stage4 |
8.800400E-02 |
| Stage2-vs-Stage3 |
8.568800E-04 |
| Stage2-vs-Stage4 |
2.618000E-04 |
| Stage3-vs-Stage4 |
4.339800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.15639999995498E-06 |
| Normal-vs-AfricanAmerican |
1.423210E-01 |
| Normal-vs-Asian |
5.629400E-04 |
| Caucasian-vs-AfricanAmerican |
1.321180E-01 |
| Caucasian-vs-Asian |
9.084000E-01 |
| AfricanAmerican-vs-Asian |
1.817170E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.164990E-04 |
| Normal-vs-Female |
6.06909999999461E-05 |
| Male-vs-Female |
5.280800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.49589999999911E-05 |
| Normal-vs-Age(41-60Yrs) |
4.153100E-04 |
| Normal-vs-Age(61-80Yrs) |
1.213000E-04 |
| Normal-vs-Age(81-100Yrs) |
4.706600E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.759000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.233600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.423000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.891600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.404200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.770200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.246500E-04 |
| Classical-VS-Follicular |
1.613820E-01 |
| Classical-VS-Other |
1.119210E-01 |
| Classical-VS-Normal |
9.79070000000082E-05 |
| Tall-VS-Follicular |
1.820420E-04 |
| Tall-VS-Other |
7.523800E-01 |
| Tall-VS-Normal |
6.26959999472376E-08 |
| Follicular-VS-Other |
7.746000E-02 |
| Follicular-VS-Normal |
4.276000E-02 |
| Other-VS-Normal |
3.523300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.675570E-03 |
| Normal-vs-N1 |
3.01749999986889E-07 |
| N0-vs-N1 |
2.435400E-03 |
|
|
